Global equity funds attracted significant inflows in the week ending February 12, after a Bank of England rate cut drove a ...

Havant MP Alan Mak has demanded to know why the Labour Government chose to walk away from a £450m investment deal with ...

Sumitomo Mitsui Trust Group Inc. grew its stake in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 0.7% during the 4th quarter, according to its most recent 13F filing with the Securities & ...

Fintel reports that on February 13, 2025, UBS upgraded their outlook for AstraZeneca PLC - Depositary Receipt () ...

Before taking its repurposed diabetes drug candidate into a phase 2 lupus trial, Conduit Pharmaceuticals is tapping Charles River Laboratories to help test the asset in a preclinical model of the ...

Dr. Tycel Phillips discusses the implications of the FDA approval of Calquence plus bendamustine and Rituxan in previously untreated mantle cell lymphoma.

UBS upgraded AstraZeneca (AZN) to Buy from Neutral with a price target of 14,200 GBp, up from 11,500 GBp. The firm cites the company’s ...

Stephens Inc. AR lessened its position in shares of AstraZeneca PLC (NASDAQ:AZN – Free Report) by 5.2% in the fourth quarter, Holdings Channel reports. The fund owned 24,987 shares of the company’s ...

The FDA on Tuesday signed off on SpringWorks Therapeutics’ mirdametinib—now to carry the brand name Gomekli—for the treatment ...

Alexion, AstraZeneca Rare Disease, and DHL Express announced a partnership to reduce greenhouse gas emissions (GHG) from the ...

Morgan Stanley analyst Sarita Kapila initiated coverage of AstraZeneca (AZN) with an Overweight rating and 14,500 GBp price target The firm ...

Immunotherapy, which uses programmed immune cells to selectively destroy cancer cells, has transformed cancer treatment.